MiR-192-5p regulates lipid synthesis in non-Alcoholic fatty liver disease through SCD-1

World Journal of Gastroenterology

Volumn 23, Issue 46, 2017, Pages 8140-8151

  Liu, Xiao Lin ^a   Cao, Hai Xia ^a   Wang, Bao Can ^a   Xin, Feng Zhi ^a   Zhang, Rui Nan ^a   Zhou, Da ^a   Yang, Rui Xu ^a   Zhao, Ze Hua ^a   Pan, Qin ^a   Fan, Jian Gao ^a  

^a XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

High fat diet; Lipid synthesis; MiR 192 5p; Non Alcoholic fatty liver disease; Stearoyl coa desaturase 1

Indexed keywords

LIPID; LIRAGLUTIDE; MICRORNA 192; MICRORNA 192 5P; OXYGENASE; PALMITIC ACID; SMALL INTERFERING RNA; STEAROYL COENZYME A DESATURASE 1; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ACYL COENZYME A DESATURASE; MICRORNA; STEAROYL-COA DESATURASE SCD-1, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; GENE REPRESSION; GENETIC TRANSFECTION; HUH-7 CELL LINE; LIPID DIET; LIPOGENESIS; LUCIFERASE ASSAY; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; RAT; REMISSION; REPORTER GENE; RNA ANALYSIS; STAINING; TREATMENT DURATION; UPREGULATION; ANIMAL; DISEASE MODEL; DRUG EFFECT; GENE KNOCKDOWN; GENETICS; HUMAN; LIVER; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; DOWN-REGULATION; GENE KNOCKDOWN TECHNIQUES; HUMANS; LIPOGENESIS; LIRAGLUTIDE; LIVER; MALE; MICRORNAS; NON-ALCOHOLIC FATTY LIVER DISEASE; PALMITIC ACID; RATS; RATS, SPRAGUE-DAWLEY; RNA, SMALL INTERFERING; STEAROYL-COA DESATURASE; UP-REGULATION;

EID: 85038440795     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v23.i46.8140     Document Type: Article

References (43)

1. Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol 2017; 67: 862-873 [PMID: 28642059 DOI:10.1016/j.jhep.2017.06.003].
2. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43: S99-S112 [PMID: 16447287 DOI:10.1002/hep.20973].
3. Wong VW, Wong GL, Choi PC, Chan AW, Li MK, Chan HY, Chim AM, Yu J, Sung JJ, Chan HL. Disease progression of nonalcoholic fatty liver disease: A prospective study with paired liver biopsies at 3 years. Gut 2010; 59: 969-974 [PMID: 20581244 DOI:10.1136/gut.2009.205088].
4. Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-Alcoholic fatty liver disease (NAFLD). Metabolism 2016; 65: 1038-1048 [PMID: 26823198 DOI:10.1016/j.metabol.2015.12.012].
5. Sookoian S, Rosselli MS, Gemma C, Burgueño AL, Fernández Gianotti T, Castaño GO, Pirola CJ. Epigenetic regulation of insulin resistance in nonalcoholic fatty liver disease: impact of liver methylation of the peroxisome proliferator-Activated receptor γ coactivator 1α promoter. Hepatology 2010; 52: 1992-2000 [PMID: 20890895 DOI:10.1002/hep.23927].
6. Liu XL, Cao HX, Fan JG. MicroRNAs as biomarkers and regulators of nonalcoholic fatty liver disease. J Dig Dis 2016; 17: 708-715 [PMID: 27628945 DOI:10.1111/1751-2980.12408].
7. Sun C, Fan JG, Qiao L. Potential epigenetic mechanism in nonalcoholic Fatty liver disease. Int J Mol Sci 2015; 16: 5161-5179 [PMID: 25751727 DOI:10.3390/ijms16035161].
8. Pirola CJ, Gianotti TF, Burgueño AL, Rey-Funes M, Loidl CF, Mallardi P, Martino JS, Castaño GO, Sookoian S. Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease. Gut 2013; 62: 1356-1363 [PMID: 22879518 DOI:10.1136/gutjnl-2012-302962].
9. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297 [PMID: 14744438 DOI:10.1016/S0092-8674(04)00045-5].
10. Rottiers V, Näär AM. MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol 2012; 13: 239-250 [PMID: 22436747 DOI:10.1038/nrm3313].
11. Pirola CJ, Fernández Gianotti T, Castaño GO, Mallardi P, San Martino J, Mora Gonzalez Lopez Ledesma M, Flichman D, Mirshahi F, Sanyal AJ, Sookoian S. Circulating microRNA signature in non-Alcoholic fatty liver disease: from serum noncoding RNAs to liver histology and disease pathogenesis. Gut 2015; 64: 800-812 [PMID: 24973316 DOI:10.1136/gutjnl-2014-306996].
12. Liu XL, Pan Q, Zhang RN, Shen F, Yan SY, Sun C, Xu ZJ, Chen YW, Fan JG. Disease-specific miR-34a as diagnostic marker of non-Alcoholic steatohepatitis in a Chinese population. World J Gastroenterol 2016; 22: 9844-9852 [PMID: 27956809 DOI:10.3748/wjg.v22.i44.9844].
13. Roy S, Benz F, Alder J, Bantel H, Janssen J, Vucur M, Gautheron J, Schneider A, Schüller F, Loosen S, Luedde M, Koch A, Tacke F, Luedde T, Trautwein C, Roderburg C. Down-regulation of miR- 192-5p protects from oxidative stress-induced acute liver injury. Clin Sci (Lond) 2016; 130: 1197-1207 [PMID: 27129188 DOI:10.1042/CS20160216].
14. Lian J, Jing Y, Dong Q, Huan L, Chen D, Bao C, Wang Q, Zhao F, Li J, Yao M, Qin L, Liang L, He X. miR-192, a prognostic indicator, targets the SLC39A6/SNAIL pathway to reduce tumor metastasis in human hepatocellular carcinoma. Oncotarget 2016; 7: 2672-2683 [PMID: 26684241 DOI:10.18632/oncotarget.6603].
15. Lambert JE, Ramos-Roman MA, Browning JD, Parks EJ. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology 2014; 146: 726-735 [PMID: 24316260 DOI:10.1053/j.gastro.2013.11.049].
16. Saponaro C, Gaggini M, Carli F, Gastaldelli A. The Subtle Balance between Lipolysis and Lipogenesis: A Critical Point in Metabolic Homeostasis. Nutrients 2015; 7: 9453-9474 [PMID: 26580649 DOI:10.3390/nu7115475].
17. Miyazaki M, Dobrzyn A, Man WC, Chu K, Sampath H, Kim HJ, Ntambi JM. Stearoyl-CoA desaturase 1 gene expression is necessary for fructose-mediated induction of lipogenic gene expression by sterol regulatory element-binding protein-1cdependent and -independent mechanisms. J Biol Chem 2004; 279: 25164-25171 [PMID: 15066988 DOI:10.1074/jbc.M402781200].
18. Krauskopf J, Caiment F, Claessen SM, Johnson KJ, Warner RL, Schomaker SJ, Burt DA, Aubrecht J, Kleinjans JC. Application of high-Throughput sequencing to circulating microRNAs reveals novel biomarkers for drug-induced liver injury. Toxicol Sci 2015; 143: 268-276 [PMID: 25359176 DOI:10.1093/toxsci/kfu232].
19. Brunetto MR, Cavallone D, Oliveri F, Moriconi F, Colombatto P, Coco B, Ciccorossi P, Rastelli C, Romagnoli V, Cherubini B, Teilum MW, Blondal T, Bonino F. A serum microRNA signature is associated with the immune control of chronic hepatitis B virus infection. PLoS One 2014; 9: E110782 [PMID: 25350115 DOI:10.1371/journal.pone.0110782].
20. Zhu HT, Liu RB, Liang YY, Hasan AME, Wang HY, Shao Q, Zhang ZC, Wang J, He CY, Wang F, Shao JY. Serum microRNA profiles as diagnostic biomarkers for HBV-positive hepatocellular carcinoma. Liver Int 2017; 37: 888-896 [PMID: 28061012 DOI:10.1111/liv.13356].
21. Wen Y, Han J, Chen J, Dong J, Xia Y, Liu J, Jiang Y, Dai J, Lu J, Jin G, Han J, Wei Q, Shen H, Sun B, Hu Z. Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma. Int J Cancer 2015; 137: 1679-1690 [PMID: 25845839 DOI:10.1002/ijc.29544].
22. Becker PP, Rau M, Schmitt J, Malsch C, Hammer C, Bantel H, Müllhaupt B, Geier A. Performance of Serum microRNAs -122, -192 and -21 as Biomarkers in Patients with Non-Alcoholic Steatohepatitis. PLoS One 2015; 10: E0142661 [PMID: 26565986 DOI:10.1371/journal.pone.0142661].
23. Castoldi M, Vujic Spasic M, Altamura S, Elmén J, Lindow M, Kiss J, Stolte J, Sparla R, D'Alessandro LA, Klingmüller U, Fleming RE, Longerich T, Gröne HJ, Benes V, Kauppinen S, Hentze MW, Muckenthaler MU. The liver-specific microRNA miR-122 controls systemic iron homeostasis in mice. J Clin Invest 2011; 121: 1386-1396 [PMID: 21364282 DOI:10.1172/JCI44883].
24. Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M, Watts L, Booten SL, Graham M, McKay R, Subramaniam A, Propp S, Lollo BA, Freier S, Bennett CF, Bhanot S, Monia BP. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006; 3: 87-98 [PMID: 16459310 DOI:10.1016/j.cmet.2006.01.005].
25. Ding J, Li M, Wan X, Jin X, Chen S, Yu C, Li Y. Effect of miR- 34a in regulating steatosis by targeting PPARα expression in nonalcoholic fatty liver disease. Sci Rep 2015; 5: 13729 [PMID: 26330104 DOI:10.1038/srep13729].
26. Xu Y, Zalzala M, Xu J, Li Y, Yin L, Zhang Y. A metabolic stressinducible miR-34a-HNF4α pathway regulates lipid and lipoprotein metabolism. Nat Commun 2015; 6: 7466 [PMID: 26100857 DOI:10.1038/ncomms8466].
27. Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, Hazlehurst JM, Guo K,; LEAN trial team, Abouda G, Aldersley MA, Stocken D, Gough SC, Tomlinson JW, Brown RM, Hübscher SG, Newsome PN. Liraglutide safety and efficacy in patients with non-Alcoholic steatohepatitis (LEAN): A multicentre, doubleblind, randomised, placebo-controlled phase 2 study. Lancet 2016; 387: 679-690 [PMID: 26608256 DOI:10.1016/S0140-6736(15)00803-X].
28. Geng L, Chaudhuri A, Talmon G, Wisecarver JL, Are C, Brattain M, Wang J. MicroRNA-192 suppresses liver metastasis of colon cancer. Oncogene 2014; 33: 5332-5340 [PMID: 24213572 DOI:10.1038/onc.2013.478].
29. Lu H, Lei X, Liu J, Klaassen C. Regulation of hepatic microRNA expression by hepatocyte nuclear factor 4 alpha. World J Hepatol 2017; 9: 191-208 [PMID: 28217257 DOI:10.4254/wjh.v9.i4.191].
30. Jenkins RH, Martin J, Phillips AO, Bowen T, Fraser DJ. Transforming growth factor β1 represses proximal tubular cell microRNA-192 expression through decreased hepatocyte nuclear factor DNA binding. Biochem J 2012; 443: 407-416 [PMID: 22264233 DOI:10.1042/BJ20111861].
31. Gil-Zamorano J, Martin R, Daimiel L, Richardson K, Giordano E, Nicod N, García-Carrasco B, Soares SM, Iglesias-Gutiérrez E, Lasunción MA, Sala-Vila A, Ros E, Ordovás JM, Visioli F, Dávalos A. Docosahexaenoic acid modulates the enterocyte Caco-2 cell expression of microRNAs involved in lipid metabolism. J Nutr 2014; 144: 575-585 [PMID: 24623846 DOI:10.3945/jn.113.189050].
32. Lin Y, Ding D, Huang Q, Liu Q, Lu H, Lu Y, Chi Y, Sun X, Ye G, Zhu H, Wei J, Dong S. Downregulation of miR-192 causes hepatic steatosis and lipid accumulation by inducing SREBF1: Novel mechanism for bisphenol A-Triggered non-Alcoholic fatty liver disease. Biochim Biophys Acta 2017; 1862: 869-882 [PMID: 28483554 DOI:10.1016/j.bbalip.2017.05.001].
33. Marchesini G, Petta S, Dalle Grave R. Diet, weight loss, and liver health in nonalcoholic fatty liver disease: Pathophysiology, evidence, and practice. Hepatology 2016; 63: 2032-2043 [PMID: 26663351 DOI:10.1002/hep.28392].
34. Rotman Y, Sanyal AJ. Current and upcoming pharmacotherapy for non-Alcoholic fatty liver disease. Gut 2017; 66: 180-190 [PMID: 27646933 DOI:10.1136/gutjnl-2016-312431].
35. Bechmann LP, Hannivoort RA, Gerken G, Hotamisligil GS, Trauner M, Canbay A. The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol 2012; 56: 952-964 [PMID: 22173168 DOI:10.1016/j.jhep.2011.08.025].
36. Liu L, Wang S, Yao L, Li JX, Ma P, Jiang LR, Ke DZ, Pan YQ, Wang JW. Long-Term fructose consumption prolongs hepatic stearoyl-CoA desaturase 1 activity independent of upstream regulation in rats. Biochem Biophys Res Commun 2016; 479: 643-648 [PMID: 27697525 DOI:10.1016/j.bbrc.2016.09.160].
37. Paton CM, Ntambi JM. Biochemical and physiological function of stearoyl-CoA desaturase. Am J Physiol Endocrinol Metab 2009; 297: E28-E37 [PMID: 19066317 DOI:10.1152/ajpendo.90897.2008].
38. Flowers MT, Ntambi JM. Role of stearoyl-coenzyme A desaturase in regulating lipid metabolism. Curr Opin Lipidol 2008; 19: 248-256 [PMID: 18460915 DOI:10.1097/MOL.0b013e3282f9b54d].
39. Hyun CK, Kim ED, Flowers MT, Liu X, Kim E, Strable M, Ntambi JM. Adipose-specific deletion of stearoyl-CoA desaturase 1 up-regulates the glucose transporter GLUT1 in adipose tissue. Biochem Biophys Res Commun 2010; 399: 480-486 [PMID: 20655875 DOI:10.1016/j.bbrc.2010.07.072].
40. Miyazaki M, Sampath H, Liu X, Flowers MT, Chu K, Dobrzyn A, Ntambi JM. Stearoyl-CoA desaturase-1 deficiency attenuates obesity and insulin resistance in leptin-resistant obese mice. Biochem Biophys Res Commun 2009; 380: 818-822 [PMID: 19338759 DOI:10.1016/j.bbrc.2009.01.183].
41. Cheng X, Xi QY, Wei S, Wu D, Ye RS, Chen T, Qi QE, Jiang QY, Wang SB, Wang LN, Zhu XT, Zhang YL. Critical role of miR-125b in lipogenesis by targeting stearoyl-CoA desaturase-1 (SCD-1). J Anim Sci 2016; 94: 65-76 [PMID: 26812313 DOI:10.2527/jas.2015-9456].
42. Qiang J, Tao YF, He J, Sun YL, Xu P. miR-29a modulates SCD expression and is regulated in response to a saturated fatty acid diet in juvenile genetically improved farmed tilapia (Oreochromis niloticus). J Exp Biol 2017; 220: 1481-1489 [PMID: 28167804 DOI:10.1242/jeb.151506].
43. Jonas S, Izaurralde E. Towards a molecular understanding of microRNA-mediated gene silencing. Nat Rev Genet 2015; 16: 421-433 [PMID: 26077373 DOI:10.1038/nrg3965].